Released Aug 16, 2021, during market hours
10-Q filed Aug 16, 2021, 47 days after period end · 0000950170-21-001486
Q2 2021 · 10-Q
Revenue—
Net Income-$55.80M-$55.80M N/M vs Q2 2020N/M vs Q1 2021
EPS Diluted-$1.07-$1.07 N/M vs Q2 2020N/M vs Q1 2021
Operating Income-$55,689,000N/M
Operating Cash Flowderived-$5,939,000N/M
Free Cash Flowderived-$6,235,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2021 | Q2 2020 | Q2 2019 |
|---|---|---|---|
| Net Income | -$55.80M | -$5.56M | -$8.81M |
| EPS Diluted | -$1.07 | -$0.41 | -$1.33 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR